A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients



Status:Active, not recruiting
Conditions:Breast Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/26/2017
Start Date:October 2013
End Date:February 2018

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

The purpose of this study is to compare progression-free survival (PFS)in patients with
advanced/metastatic breast cancer who have a BRCA gene change when treated with niraparib as
compared to those treated with physician's choice

This is a phase III, randomized, open label, multicenter, controlled trial of niraparib
versus physician's choice in previously-treated, HER2 negative, germline BRCA
mutation-positive breast cancer patients. Niraparib is an orally active parp inhibitor.
Niraparib (in a 2:1 ratio) will be administered once daily continuously during a 21-day
cycle. Physician's choice will be administered on a 21-day cycle. Health-related quality of
life will be measured. The Safety and tolerability will be assessed by clinical review of
adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory
values.

Inclusion Criteria:

1. Germline BRCA1 or BRCA2 mutation; patients with unknown BRCA status who meet NCCN BRCA
screening criteria will be screened for BRCA mutation.

2. Metastatic or locally advanced disease that is not amenable to resection or radiation
with curative intent.

3. Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer patients
with no prior cytotoxic regimens for advanced or metastatic disease will only be
allowed if they relapsed during or within 12 months of (neo-) adjuvant cytotoxic
therapy that included a taxane and/or anthracycline, if not contraindicated.

4. Prior therapy should have included a taxane and/or anthracycline (unless
contraindication to those) in the neoadjuvant, adjuvant, or advanced/metastatic
setting.

a. Hormone receptor positive patients must also have hormone resistant disease
(progression during at least one prior hormonal therapy) for which chemotherapy is
indicated.

5. ECOG performance status 0-2

6. Adequate bone marrow, kidney and liver function

Exclusion Criteria:

1. Patients with platinum resistant cancer

2. Symptomatic uncontrolled brain metastases

3. Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a
5-year disease-free interval; Stage II ovarian cancer must have a 2-year disease-free
interval

4. Known hypersensitivity to the components of niraparib

5. Invasive cancer other than ovarian cancer within 2 years (except basal or squamous
cell carcinoma of the skin that has been definitely treated)

6. Pregnant or breast feeding patients

7. Immunocompromised patients

8. Known active Hepatitis B or C

9. Prior treatment with a PARP inhibitor

10. Known history of myelodysplastic syndrome (MDS).

11. known and persistent (>4 weeks) >/= grade 3 toxicity or fatigue from prior cancer
treatment.
We found this trial at
25
sites
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
4037
mi
from 43215
Aalst,
Click here to add this to my saved trials
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
2057
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
2001
mi
from 43215
Everett, WA
Click here to add this to my saved trials
922
mi
from 43215
Fort Myers, FL
Click here to add this to my saved trials
1751
mi
from 43215
Henderson, NV
Click here to add this to my saved trials
493
mi
from 43215
Lake Success, NY
Click here to add this to my saved trials
517
mi
from 43215
Latham, NY
Click here to add this to my saved trials
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
226
mi
from 43215
Low Moor, VA
Click here to add this to my saved trials
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
331
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
896
mi
from 43215
Plano, TX
Click here to add this to my saved trials
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
993
mi
from 43215
Webster, TX
Click here to add this to my saved trials
1285
mi
from 43215
Weslaco, TX
Click here to add this to my saved trials